Cargando…

Diabetes and Ramadan: An Update On Use of Glycemic Therapies During Fasting

The fasting of Ramadan is observed by a large proportion of Muslims with diabetes. Recommendations for the management of diabetes during Ramadan were last published in 2005 by the American Diabetes Association. Several studies in this field have since been published, some addressing the use of new p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Mohamed H., Abdu, Tarig A. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156519/
https://www.ncbi.nlm.nih.gov/pubmed/21727749
http://dx.doi.org/10.4103/0256-4947.81802
_version_ 1782210200537661440
author Ahmed, Mohamed H.
Abdu, Tarig A. M.
author_facet Ahmed, Mohamed H.
Abdu, Tarig A. M.
author_sort Ahmed, Mohamed H.
collection PubMed
description The fasting of Ramadan is observed by a large proportion of Muslims with diabetes. Recommendations for the management of diabetes during Ramadan were last published in 2005 by the American Diabetes Association. Several studies in this field have since been published, some addressing the use of new pharmacological agents in managing diabetes during Ramadan. The incritin memetics are potentially safe during Ramadan; the DPP4 inhibitors vildagliptin and sitagliptin provide an effective and safe therapeutic option, administered either alone or in combination with metformin or sulfonylureas. There are no published studies on the use of GLP-1 receptor agonists during Ramadan. Among the sulfonylureas, gliclazide MR (modified release) and glimepride can be safely used during Ramadan, but glibenclamide should be avoided due to the associated risk of hypoglycemia. In selected patients with type 1 and type 2 diabetes, the long-acting insulin analogues glargine and detemir, as well as the premixed insulin analogues, can be used with minimal risk of metabolic derangement or hypoglycemia; the risk is higher in type 1 diabetes. Insulin pumps can potentially empower patients with diabetes and enable safe fasting during the month of Ramadan. Further clinical trials are needed to evaluate the safety and efficacy of new antidiabetic agents and new diabetes-related technologies during Ramadan.
format Online
Article
Text
id pubmed-3156519
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-31565192011-09-06 Diabetes and Ramadan: An Update On Use of Glycemic Therapies During Fasting Ahmed, Mohamed H. Abdu, Tarig A. M. Ann Saudi Med Review The fasting of Ramadan is observed by a large proportion of Muslims with diabetes. Recommendations for the management of diabetes during Ramadan were last published in 2005 by the American Diabetes Association. Several studies in this field have since been published, some addressing the use of new pharmacological agents in managing diabetes during Ramadan. The incritin memetics are potentially safe during Ramadan; the DPP4 inhibitors vildagliptin and sitagliptin provide an effective and safe therapeutic option, administered either alone or in combination with metformin or sulfonylureas. There are no published studies on the use of GLP-1 receptor agonists during Ramadan. Among the sulfonylureas, gliclazide MR (modified release) and glimepride can be safely used during Ramadan, but glibenclamide should be avoided due to the associated risk of hypoglycemia. In selected patients with type 1 and type 2 diabetes, the long-acting insulin analogues glargine and detemir, as well as the premixed insulin analogues, can be used with minimal risk of metabolic derangement or hypoglycemia; the risk is higher in type 1 diabetes. Insulin pumps can potentially empower patients with diabetes and enable safe fasting during the month of Ramadan. Further clinical trials are needed to evaluate the safety and efficacy of new antidiabetic agents and new diabetes-related technologies during Ramadan. Medknow Publications 2011 /pmc/articles/PMC3156519/ /pubmed/21727749 http://dx.doi.org/10.4103/0256-4947.81802 Text en © Annals of Saudi Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Ahmed, Mohamed H.
Abdu, Tarig A. M.
Diabetes and Ramadan: An Update On Use of Glycemic Therapies During Fasting
title Diabetes and Ramadan: An Update On Use of Glycemic Therapies During Fasting
title_full Diabetes and Ramadan: An Update On Use of Glycemic Therapies During Fasting
title_fullStr Diabetes and Ramadan: An Update On Use of Glycemic Therapies During Fasting
title_full_unstemmed Diabetes and Ramadan: An Update On Use of Glycemic Therapies During Fasting
title_short Diabetes and Ramadan: An Update On Use of Glycemic Therapies During Fasting
title_sort diabetes and ramadan: an update on use of glycemic therapies during fasting
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156519/
https://www.ncbi.nlm.nih.gov/pubmed/21727749
http://dx.doi.org/10.4103/0256-4947.81802
work_keys_str_mv AT ahmedmohamedh diabetesandramadananupdateonuseofglycemictherapiesduringfasting
AT abdutarigam diabetesandramadananupdateonuseofglycemictherapiesduringfasting